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Upregulation of Ecto-5-Nucleotidase by Rosuvastatin
Increases the Vasodilator Response to Ischemia
Patrick Meijer, Constantijn W. Wouters, Petra H.H. van den Broek, Maarten de Rooij,
Gert Jan Scheffer, Paul Smits, Gerard A. Rongen
Abstract—3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are effective in the primary and
secondary prevention of cardiovascular events. Although originally developed to improve lipid profile, statins have
demonstrated a surplus of beneficial pleiotropic effects, including improved endothelial function, reduced inflammation,
and increased tolerance to ischemia-reperfusion injury. In preclinical studies, increased ecto-5-nucleotidase activity, the
key enzyme in extracellular adenosine formation, plays an important role in these effects. Because human data are
absent, we explored the effects of rosuvastatin on ecto-5-nucleotidase activity and the clinical relevance of increased
extracellular adenosine during ischemia in humans in vivo. The forearm vasodilator responses to 3 increasing periods
of forearm ischemia (2, 5, and 13 minutes) were determined during placebo and caffeine (an adenosine receptor
antagonist) infusion into the brachial artery. At the end of an 8-day treatment period with rosuvastatin (20 mg per day),
this whole procedure was repeated. During both experiments, ecto-5-nucleotidase activity was determined. Vasodilator
responses are expressed as the percentage increase in forearm blood flow ratio from baseline. Rosuvastatin increased
ecto-5-nucleotidase activity by 4917% and enhanced the vasodilator response after 2, 5, and 13 minutes of ischemia
in the absence (14619, 33026, and 987133 to 31277, 566107, and 1533267) but not in the presence of
caffeine (9825, 26454, and 727111 versus 9519, 20534, and 53062). Rosuvastatin increases extracellular
formation of adenosine in humans in vivo probably by enhancing ecto-5-nucleotidase activity. This action results in the
improvement of reactive hyperemia and may further enhance the clinical benefit of statins, in particular in conditions
of ischemia. (Hypertension. 2010;56:722-727.)
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3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase in-hibitors (statins) are effective in the primary and second-
ary prevention of cardiovascular events.1,2 Although origi-
nally developed to improve lipid profile, statins have
demonstrated a surplus of beneficial pleiotropic effects,
including improved endothelial function, reduced inflammation,
and increased tolerance to ischemia-reperfusion injury.3–7 These
effects are independent of plasma cholesterol lowering and
improve outcome after cardiovascular events.8,9
Increased extracellular adenosine formation has been im-
plicated as one of the underlying mechanisms. This is
supported by several preclinical studies demonstrating the
activation of ecto-5-nucleotidase (CD73) activity, increased
stimulation of adenosine receptors, and adenosine-mediated
protection against ischemia-reperfusion injury by statins.10–12
The enzyme CD73 dephosphorylates extracellular AMP,
which forms the rate-limiting step in the formation of
extracellular adenosine.13 We recently demonstrated in-
creased extracellular adenosine formation in healthy human
volunteers after a 1-week treatment with rosuvastatin using a
pharmacological approach. In addition, we demonstrated
rosuvastatin-induced augmentation of postocclusive reactive
hyperemia (PORH).5 However, we did not assess CD73
activity as a potential source of extracellular adenosine, nor
did we investigate the role of adenosine in rosuvastatin-
induced augmentation of PORH. CD73 activity plays a
pivotal role in the formation of atherosclerosis and increased
cellular resilience against ischemia-reperfusion injury ob-
served after ischemic preconditioning.14–16 An increase in
CD73 activity may therefore reduce atherosclerosis formation
and improve cellular tolerance against ischemia. The extent
of PORH in the human forearm correlates well with the
vasodilator impairment in the coronary circulation.17 Indeed,
it reflects vascular health status, because increased forearm
PORH is associated with a reduced incidence of stroke and
cardiovascular disease in patients with essential hyperten-
sion.18 Compared with normotensive subjects patients with
essential hypertension have a reduced vasodilator response to
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reactive hyperemia and may therefore benefit from therapies
aimed at or associated with an improvement of PORH.19
Insight into the underlying mechanism of rosuvastatin-
induced augmentation of reactive hyperemia may help us in
optimizing the beneficial effects of statins and improve
treatment of patients at risk for cardiovascular events. We,
therefore, assessed the involvement of adenosine in
rosuvastatin-induced augmentation of PORH by testing the
following hypotheses: a 1-week treatment with rosuvastatin
enhances CD73 activity of circulating mononuclear blood
cells, and caffeine, an adenosine receptor antagonist, inhibits
the effect of rosuvastatin on forearm PORH.
Methods
Subjects
The study was performed in accordance with the Declaration of
Helsinki of the World Medical Association and approved by the
institutional review board of the Radboud University Nijmegen
Medical Centre. Ten healthy volunteers (5 women; aged 19 to 24
years) with a normal medical history, physical examination, blood
pressure, body mass index, fasting plasma lipid profile, and glucose
concentration gave written informed consent before entering the
study. Experiments were performed in a temperature-controlled
room (231°C) in the morning after an overnight fast and 24
hours of caffeine abstinence. All of the experiments were performed
according to institutional guidelines.
Procedures
At the start of each experiment, a 27-gauge needle (B. Braun Medical
B.V.) was inserted into the brachial artery of the nondominant arm
for intra-arterial drug administration. In both arms, forearm blood
flow (FBF) was measured simultaneously with venous occlusion
plethysmography using mercury-in-silastic-strain gauges and oc-
cluded hand circulation as described previously.20
Experimental Design
Figure 1 shows the design of the study. All volunteers received an
8-day treatment with rosuvastatin (20 mg per day) and entered our
research facility twice, the first time before the start of treatment with
rosuvastatin and the second time on the final day of treatment with
rosuvastatin. On both visits forearm vasodilator responses to 3
increasing periods of forearm ischemia (2, 5, and 13 minutes) were
determined, once during the infusion of placebo (saline 0.9%, 50
L/min per 100 mL of forearm volume) and once during the
administration of caffeine (90 g/min per 100 mL of forearm
volume) into the brachial artery.
Ecto-5-Nucleotidase Activity
We determined the activity of CD73 exposed on the surface of intact
mononuclear cells by quantifying the conversion of 1,N6-
ethenoadenosine 5-monophosphate to 1,N6-ethenoadenosine21 in
the presence and absence of the CD73-specific inhibitor ,ß-
methyleneadenosine 5-diphosphate. The difference in these 2 activ-
ities reflects CD73 activity. To eliminate the influence of nonspecific
dephosphorylation of 1,N6-ethenoadenosine 5-monophosphate to
1,N6-ethenoadenosine and 1,N6-ethenoadenosine transport, CD73
activity was measured in the presence of ß-glycerophosphate and
dipyridamole. ß-Glycerophosphate forms a competitive substrate for
nonspecific phosphatases eliminating the contribution of nonspecific
dephosphorylation of AMP. Dipyridamole is an equilibrative nucle-
oside transport inhibitor that, in this concentration, prevents adeno-
sine transport across the cell membrane.
At the start of each experiment 8 mL of venous blood was sampled
and collected in cell preparation tubes (BD Vacutainer CPT), which
were centrifuged at 1600g for 20 minutes to isolate mononuclear
cells. After harvesting they were washed twice in PBS (5.39 mmol/L
of Na2HPO4, 1.29 mmol/L of KH2PO4, and 0.15 mol/L of NaCl [pH
7.4]), followed by centrifugation for 15 minutes at 319g. The
obtained pellets were resuspended in 1 mL of Hanks’ balanced salt
solution (Invitrogen).
Pilot experiments were performed to confirm optimal (Vmax)
(maximum CD73 velocity) substrate concentrations (data not
shown). For analysis, 30 L of homogenate were buffered in Hanks’
balanced salt solution containing 10.0 mmol/L of MgCl2,
10.8 mmol/L of ß-glycerophosphate, 20 mol/L of dipyridamole,
and 0.2 mmol/L of 1,N6-ethenoadenosine 5-monophosphate with or
without 400 mol/L of ,ß-methyleneadenosine 5-diphosphate. All
of the assays were performed for 5 minutes at 37°C in a total volume
of 100 L. The reaction was terminated by adding 50 L of
perchloric acid 70% and the obtained lysate centrifuged for 3
minutes. The supernatant was used for measurement of 1,N6-
ethenoadenosine concentration by ion-paired reverse-phase high-
performance liquid chromatography with fluorescence detection set
at 280/420 nm. For separation, an altima HP C18 AQ column was
used with a mobile phase containing 50 mmol/L of NH4H2PO4,
5 mmol/L of hexane sulfonic acid (pH 3.0), and acetonitrile as the
organic modifier.
Other Analytic Procedures
In all of the volunteers, blood was collected before and at the end of
oral treatment to determine fasting serum lipid profile with a
commercially available kit (Aeroset, Abbott). Compliance to caf-
feine abstinence was monitored by determination of plasma caffeine
concentration before each experiment. Plasma caffeine concentra-
tions were determined by use of reversed-phase high-performance
liquid chromatography with UV detection set at 273 nm according to
Schreiber-Deturmeny and Bruguerolle.22
Solutions
The caffeine (Genfarma) solution was freshly prepared to reach a
final syringe concentration of 90 g per 50 L. Rosuvastatin tablets
contained 20 mg per tablet and were obtained from Astra Zeneca SA.
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Figure 1. Schematic overview of the experimental protocol, indicating arterial occlusion, placebo and caffeine infusion, and FBF mea-
surements. In addition, the graph above the protocol represents the absolute FBFs, at baseline and reperfusion, in the experimental
and control arms (n8).
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Statistical Analysis
All of the CD73 activity measurements were performed in duplicate,
averaged for each subject and visit, and differences between the 2
visits were analyzed by paired t tests. To correct for random changes
in FBF unrelated to the intervention, the ratio of simultaneously
measured FBF in intervention and control arms was calculated (FBF
ratio). The FBF ratios of the last 4 minutes of reference measure-
ments (during intra-arterial saline or caffeine, as appropriate) and
first 3 minutes of each reperfusion period were averaged to 1 value.
To reduce the influence of intra-individual changes between visits
and interindividual variations in the baseline FBF ratio, results are
expressed as the percentage increase in FBF ratio from baseline
measurements. An ANOVA for repeated measures was performed
on FBF ratio with rosuvastatin, caffeine, and arterial occlusion time
as within-subject factors to determine the effect of caffeine on
rosuvastatin-enhanced PORH. Results are expressed as meanSE.
Results
The experiments were successful in 8 volunteers. Baseline
serum caffeine concentrations were 1.5 mg/L during both
experimental days, indicating adequate compliance to the
caffeine-free diet. Treatment with rosuvastatin significantly
reduced fasting total cholesterol and low-density lipoprotein
cholesterol (Table).
Ecto-5-Nucleotidase Activity
Rosuvastatin significantly increased CD73 activity with
4917% compared with baseline (Figure 2).
Forearm Circulation
The absolute changes in FBF are presented in Figure 1. FBF
ratio returned to baseline before the start of the second set of
ischemic challenges on each study day. Rosuvastatin treat-
ment did not influence baseline FBF ratios nor the course of
FBF in the control arm between study days. Rosuvastatin
treatment significantly increased the vasodilator response to
reactive hyperemia (Figure 3). In the presence of caffeine,
this augmentation of the vasodilator response was abolished.
When analyzing both experimental days separately, caffeine
significantly altered the vasodilator response to reactive
hyperemia while on rosuvastatin (P0.03) but not during
baseline conditions (before rosuvastatin treatment, P0.2).
Discussion
We recently demonstrated by using a pharmacological ap-
proach that rosuvastatin increases extracellular adenosine
formation. We now demonstrate that this is at least partly
mediated by increased CD73 activity. In addition, we under-
line the clinical relevance of the increased adenosine forma-
tion as it augments PORH after rosuvastatin treatment.
Rosuvastatin Increases Ecto-5-Nucleotidase
Previous studies already reported on the stimulatory effect of
statins on CD73 activity. This was demonstrated for lovastat-
in in rat endothelial cells,10 pitavastatin in canine in vivo,11
and atorvastatin in human vascular endothelial cells.23 Our
results support these previous findings and are the first to
demonstrate this effect in a human in vivo setting. The under-
lying mechanism still has to be unraveled. Inhibition of meval-
onate is one of the potential mechanisms, because it not only
reduces the synthesis of cholesterol but also isoprenoids, which
are implicated in isoprenylation of small GTPases, including
members of the Rho family. Inhibition of Rho may result in
reduced endocytosis of CD73 and subsequently increased ex-
pression of CD73 on the cell membrane.10 It has also been
demonstrated that phosphatidylinositol 3-kinase and protein
kinase C may influence CD73 activity by influencing its phos-
phorylation state and may thereby form an alternative route for
statin-induced enhancement of CD73 activity.11,24 Regardless of
the underlying mechanism, activation of CD73 by statins is
likely to contribute to the clinical efficacy of statins in a setting
of cardiac infarction, because inhibition of CD73 attenuates the
limiting effect of statins on infarct size in animals.11 Further-
more, we have shown previously in a human forearm model of
ischemia-reperfusion injury that endogenous adenosine is likely
to contribute in rosuvastatin-induced protection against ische-
mia-reperfusion injury.5
Rosuvastatin Enhances PORH in the Absence But
Not in the Presence of Caffeine
The additional increase in PORH provided by rosuvastatin
was abolished by the adenosine receptor antagonist caffeine
indicating the involvement of enhanced adenosine receptor
stimulation. Previous observations already showed that rosu-
vastatin did not affect the vasodilator response to adenosine,
which excludes an effect of rosuvastatin on adenosine clear-
ance, adenosine receptors, or postreceptor signaling.5 Thus,
the increased adenosine receptor stimulation observed during
this study results from increased availability of extracellular
adenosine. This conclusion is supported by data from the
Table. Effect of Treatment With Rosuvastatin on Lipid Profile
Biochemistry Day 1 Day 8
Fasting total cholesterol, mmol/L 4.20.1 3.30.1*
Fasting low-density lipoprotein cholesterol,
mmol/L
2.30.1 1.50.1*
Fasting triglycerides, mmol/L 1.00.1 0.80.1
Fasting high-density lipoprotein cholesterol,
mmol/L
1.40.1 1.40.1
Data are expressed as meanSE.
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Figure 2. Ecto-5-nucleotidase (CD73) activity of intact mononu-
clear cells. Experiments were performed in the presence and
absence of the specific CD73 inhibitor ,ß-methyleneadenosine
5-diphosphate (AMP-CP). The difference between these two
measurements reflects CD73 activity (bars). *P0.05, data are
meanSE (n8).
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current study indicating activation of CD73 on mononuclear
cells as a result of treatment with rosuvastatin.
Potential limitations to our study design need to be ad-
dressed. First, because this study was neither randomized nor
placebo controlled, a nonspecific time effect could have
interfered. However, we have shown previously that repeated
ischemia on a single day25 or with a 1-week interval26 results
in similar reactive hyperemia. This observation makes it
superfluous to explore potential carryover effects in this
study. We opted for a limited study design to reduce the
experimental load for our volunteers as much as possible.
Second, we did not test the effect of caffeine on an adeno-
sine-independent vasodilator, and, therefore, our findings
may potentially be the result of adenosine-independent ef-
fects. A previous study from our institute demonstrated that
intra-arterial caffeine (90 g/min per 100 mL of forearm
volume) did not influence the vasodilator response to the
endothelium-independent vasodilator sodium nitroprusside,
which rules out a nonspecific effect of caffeine on PORH.27
Implications of Our Observations
Atherosclerosis is an inflammatory disease of large- and
medium-sized arteries and the most important precursor of
cardiovascular disease. Studies in atherosclerosis-susceptible
mice, including CD73-deficient mice, demonstrate the corre-
lation between reduced CD73 activity and enhanced vascular
inflammation and subsequent atherosclerosis formation.14,16
Therefore, increased CD73 activity may aid in the prevention
of atherosclerosis. In addition, inhibition of CD73 or targeted
gene deletion of CD73 intervenes with the infarct size-
limiting effect of ischemic preconditioning.15,28 This effect
can be restored by administration of soluble CD73. Adeno-
sine forms the likely mediator of CD73-dependent effects,
because its activity is functionally associated with increased
adenosine receptor stimulation.29 This is also in line with the
observation that administration of an adenosine receptor
agonist restored the proinflammatory state of CD73-deficient
mice to baseline wild-type values.16 However, because we did
not measure other adenosine forming enzymes, for example,
alkaline phosphatase, we cannot rule out a significant contri-
bution of this enzyme in rosuvastatin-induced augmentation
of adenosine formation.
Reactive hyperemia in the human forearm depends on
postocclusive dilation of arteriolar resistance vessels and
correlates well with the degree of vasodilator impairment in
the coronary circulation.17 Indeed, PORH correlates with the
incidence of cardiovascular events in patients with essential
hypertension and decreases with an increase in cardiovascular
risk factors.18,30 In addition, the extent of PORH after
coronary angioplasty reflects the clinical effectiveness of
revascularization.31 These findings support the use of PORH
as a marker for cardiovascular disease and effectiveness of
treatment. The improvement of reactive hyperemia by rosu-
vastatin, therefore, at least in part, represents its therapeutic
effect. This effect is attenuated by caffeine, which supports
the involvement of adenosine in rosuvastatin-induced effects
on cardiovascular disease.
Intake of 2 cups of coffee results in a plasma caffeine
concentration of 9 mg/L.32 In our current design we aimed
at optimal adenosine receptor blockade, which is obtained
with 90 g/min per 100 mL of forearm volume.27 During
intra-arterial infusion of caffeine, the plasma concentration in
the venous effluent depends on FBF and decreases with
higher flows. Unfortunately, we did not collect blood during
caffeine infusion and are, therefore, not able to provide
caffeine concentrations in the venous effluent in the present
study. However, in a previous trial with comparable design,20
we measured plasma caffeine concentrations after 2 and 13
minutes of arterial occlusion and 6 minutes of reperfusion
which were, respectively, 152 and 81 mg/L (meanSE,
unpublished data). This indicates that local caffeine concen-
trations in the present study approach values that occur during
regular caffeine consumption. We studied the effects of acute
caffeine administration. Previous studies have indicated the
development of (partial) tolerance to the effects of caffeine on
blood pressure. However, in chronic caffeine consumers the
blood pressure response to adenosine continuously increased
during a 2-week period of caffeine abstinence, suggesting that
the interaction between caffeine and adenosine may be less
prone to tolerance development. Therefore, we believe that
our observations strongly support the advice that patients who
are treated with statins should abstain from caffeine con-
sumption to fully utilize its clinical benefit. Additional
evidence for this advice would need a large clinical trial in
2         5                           13
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Figure 3. Percentage increase in FBF ratio after
arterial occlusion compared with baseline. P val-
ues indicate the level of significance for the
effect of rosuvastatin on FBF ratio after arterial
occlusion in the absence (left) and presence of
caffeine (right) and the interaction between rosu-
vastatin and caffeine (left versus right, ANOVA for
repeated measures). Data are meanSE (n8).
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patients treated with statins randomized to long-term regular
caffeine consumption or caffeine abstinence with mortality
and morbidity as clinical end points. Such a trial is very
expensive and, in our opinion, hardly feasible.
Perspectives
In the last 20 years statins have been shown to improve
outcome observed during acute coronary syndromes,8,9 car-
diac bypass surgery,33,34 and percutaneous coronary interven-
tions.35 The underlying mechanism is extensively studied but
nonetheless not fully understood, which may hamper the full
potential of this class of drugs. Our results demonstrate for
the first time the effect of rosuvastatin on CD73 in a human
in vivo setting and confirm the clinical relevance of increased
adenosine receptor stimulation in the beneficial effects ex-
erted by statins. These findings are of particular interest,
because pharmacological modulation, both beneficial and
detrimental, of the transport and actions of adenosine is
already in widespread use, for example, dipyridamole and
caffeine. Indeed the combination of a statin with an inhibitor
of adenosine uptake into the cell, dipyridamole and cilostazol,
and subsequent increased extracellular adenosine concentra-
tions potentiate the infarct size-limiting effect of statins in
animals.36,37 Our observations support caffeine abstinence in
patients treated with a statin to fully utilize its clinical benefit.
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